Compare HIPO & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIPO | NVCT |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | 540 | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 657.1M | 721.2M |
| IPO Year | N/A | 2021 |
| Metric | HIPO | NVCT |
|---|---|---|
| Price | $29.00 | $19.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $38.67 | $10.00 |
| AVG Volume (30 Days) | 143.7K | ★ 482.4K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.28 | N/A |
| Revenue Next Year | $22.33 | N/A |
| P/E Ratio | $7.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.08 | $5.55 |
| 52 Week High | $38.98 | $29.28 |
| Indicator | HIPO | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 64.55 | 57.65 |
| Support Level | $24.68 | $6.93 |
| Resistance Level | $29.08 | N/A |
| Average True Range (ATR) | 1.11 | 2.68 |
| MACD | 0.44 | 0.36 |
| Stochastic Oscillator | 84.38 | 49.35 |
Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.